Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Narlaprevir

Generic Name: Narlaprevir

Drug Type: Small Molecule

Chemical Formula: C_₃₆H_₆₁N_₅O_₇S

CAS Number: 865466-24-6

Unique Ingredient Identifier: 2857LA2O07

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Phase 2

Completed

Posted: 2020/01/29

Sponsor:

R-Pharm

ID:NCT04246723

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

Phase 3

Completed

Posted: 2019/02/07

Sponsor:

R-Pharm

ID:NCT03833362

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Phase 1

Completed

Posted: 2019/02/06

Sponsor:

R-Pharm

ID:NCT03832426

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Phase 1

Completed

Posted: 2018/05/25

Sponsor:

R-Pharm

ID:NCT03537404

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Phase 2

Completed

Posted: 2018/04/02

Sponsor:

R-Pharm

ID:NCT03485846

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy